The biopharmaceutical sector has witnessed a significant shift in the perception and application of single-use technologies (SUT) over the last two decades. Initially, the focus was on adoption, with industry stakeholders questioning when single-use systems would supplant traditional stainless steel setups and how far disposable bioreactors could advance. However, a recent gathering at the 2026 Bio-Process Systems Alliance (BPSA) International Single-Use Summit in Boston indicated that the dialogue has advanced. The industry has embraced single-use systems as mainstream; the pressing question now revolves around the future needs and capabilities that single-use technologies can facilitate.
Market Dynamics Post-Pandemic
Recent data from BioPlan Associates highlights a recovering industry moving beyond the disruptions of the pandemic. After a sharp decline in single-use volume growth in 2023, the market is set to rebound positively in 2024 and 2025. Eric Langer, managing partner at BioPlan Associates, characterized the industry’s current sentiment as one of “realistic optimism,” signaling a shift from pandemic-induced uncertainty to more strategic investment and decision-making.
The increase in single-use suppliers, now exceeding 200, showcases widespread adoption across all phases of biopharmaceutical development. As these technologies mature, however, expectations have escalated, indicating that the initial excitement has given way to a demand for more sophisticated solutions.
Innovations in Single-Use Technologies
The focus is shifting toward enhancing what can be accomplished with single-use technologies, emphasizing intensified processing, automation, and improved integration within manufacturing systems. Carsten Lau from Brückner Group USA noted a transition in discussions from supply chain concerns to addressing technical challenges, particularly around particulate control. This focus on quality underscores the need for collaboration across the single-use value chain, where every supplier’s contribution plays a crucial role in meeting end-user requirements.
The increasing complexity of the biopharmaceutical pipeline necessitates a new manufacturing model. By minimizing manual interventions, companies can enhance consistency and improve particulate control, ultimately boosting productivity. This collaborative approach among suppliers is essential to adapt to the evolving landscape of biopharmaceutical production.
Changing Demands in Biopharmaceutical Manufacturing
As the industry evolves, so too do its manufacturing needs. Nishant Bhasin from PwC highlighted a shift towards smaller biotech firms and precision medicine, which now represent over 60% of new drug approvals. This change signifies a departure from traditional large-scale production facilities, allowing for more flexible manufacturing strategies and smaller operational footprints.
Higher titers and improved process control are enabling manufacturers to optimize capacity while catering to a more niche patient population. This evolution emphasizes the need for scaling down production capabilities rather than solely focusing on expansion, a demand that single-use technologies are well-positioned to meet.
The Role of Continuous Processing
Continuous bioprocessing and perfusion strategies play an integral role in this new manufacturing paradigm. A significant portion of industry stakeholders anticipates exploring these approaches in the coming year. The combination of single-use technologies with intensified processing can create compact, efficient manufacturing units capable of adapting to fluctuating product demands.
For many emerging biotech companies, reliance on Contract Development and Manufacturing Organizations (CDMOs) for flexible capacity is becoming common. This partnership aligns with the industry’s shift towards smaller, agile production models that can accommodate diverse and changing therapeutic requirements.
The Necessity of Collaboration and Understanding
The BPSA Summit underscored that while single-use technologies simplify manufacturing processes, they do not eliminate the need for skilled operators and process understanding. A case study from Sanofi illustrated that innovation in single-use manufacturing requires close collaboration between technology suppliers and biopharmaceutical companies to ensure effectiveness and compliance with evolving operational demands.
As the applications of single-use systems expand, it is vital for suppliers and users to engage in meaningful dialogue to understand operational limits and ensure that products can meet the rigorous demands of intensified processes.
Building a Collaborative Ecosystem
Collaboration emerged as a key theme throughout the summit, reflecting the competitive yet cooperative nature of the single-use equipment sector. With over 200 suppliers in the space, many industry challenges cannot be addressed by individual entities alone. The BPSA facilitates an environment where competitors can work together to solve common technical issues, enhancing confidence in single-use systems across the board.
An example of this synergy was demonstrated in a joint presentation on filter interchangeability, which became a pressing concern during the pandemic. Establishing standardized definitions and frameworks for evaluating component interchangeability has been a critical step toward enhancing manufacturing resilience.
Looking Ahead: Flexibility and Resilience in Manufacturing
The emphasis on flexibility extends beyond manufacturing efficiency; it encompasses the ability to respond to future public health challenges. Robert Huffman from BARDA highlighted the importance of adaptable manufacturing technologies and robust supply networks in reinforcing the pharmaceutical industrial base.
As the industry progresses, the integration of automation and artificial intelligence will be paramount. However, suppliers must focus on creating systems that seamlessly interact and generate meaningful process data, as efficient data management is crucial for operational success.
Conclusion
The 2026 BPSA Summit illustrated a pivotal moment for single-use technologies, marking their transition from novelty to necessity. The future will be defined not only by the technologies themselves but also by how well industry players collaborate to innovate and respond to evolving demands. Single-use bioprocessing has reached maturity, and its next phase will hinge on creating agile, efficient, and resilient manufacturing systems that prioritize both technological advancement and user engagement.
- The single-use bioprocessing market is recovering post-pandemic, with a focus on more disciplined investments.
- Innovations are prioritizing intensified processing, automation, and seamless integration.
-
Smaller biotech companies are driving demand for flexible manufacturing solutions.
-
Continuous bioprocessing is becoming essential for meeting the needs of niche patient populations.
-
Collaboration among suppliers and end users is crucial for addressing the industry’s evolving challenges.
Read more → www.genengnews.com